erlotinib has been researched along with compound 968 in 2 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (compound 968) | Trials (compound 968) | Recent Studies (post-2010) (compound 968) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 23 | 0 | 22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bian, J; Li, L; Li, Z; Meng, Y; Wang, J; Xu, P; Xu, X | 1 |
2 other study(ies) available for erlotinib and compound 968
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
Topics: Animals; Benzophenanthridines; Benzoquinones; Catalytic Domain; Cell Line, Tumor; Drug Discovery; Enzyme Inhibitors; Glutaminase; Humans; Mice; Molecular Docking Simulation; Protein Binding; Sulfides; Thiadiazoles; Thiazolidinediones | 2019 |